Routine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.ObjectiveTo review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines – bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.FindingsHuman Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.Conclusions and relevanceAs these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.

中文翻译：

---

通过疫苗接种预防宫颈癌：回顾

建议全球 15 岁以下青少年常规使用人乳头瘤病毒 (HPV) 疫苗。尽管如此，由于多种因素的影响，有效的规划仍然不够理想，使得世界卫生组织根除宫颈癌的战略在公共健康方面面临着不确定的未来。目的回顾有关 HPV 疫苗接种规划和疫苗接种作为辅助管理的有效性、长期保护和安全性的文献。本综述旨在描述疫苗接种计划的现状，并展示全球范围内针对青春期女孩实施的疫苗的长期保护和安全性，以及最新公布的三种预防性 HPV 疫苗——二价 (bHPV)、四价 (qHPV) 的证据和非无价 (nHPV)-。我们主要关注评估功效、剂量方案和 HPV 疫苗接种的出版物，以及为多个国家预防性 HPV 疫苗的实际有效性提供越来越多证据的研究。调查结果人乳头瘤病毒疫苗接种计划在预防 HPV 方面取得了显着进展。相关疾病；疫苗接种工作有力的国家已见证了 HPV 相关疾病的大幅减少，其中高度宫颈异常和生殖器疣的数量也有所下降 (54%-83%)。然而，全球覆盖率仍然不平衡，高收入国家 (HIC) 和低收入国家 (LMIC) 之间存在差异。现有人乳头瘤病毒 (HPV) 的长期疗效长达 9.4 年，并且持续具有免疫原性和良好的耐受性，并且具有出色的安全性。 结论和相关性 由于这些是 HPV 疫苗接种的关键主题，因此必须建立以下系统：随着时间的推移，持续监测疫苗的免疫原性、有效性和安全性。